Patent ID: 9687492
Date: 2017-06-27
CPC Classifications: A61K,A61P

Claim:
1. A method for treating chronic lymphocytic leukemia in a human having a 17p deletion, a TP53 mutation, a NOTCH1 mutation, a SF3B1 mutation, a 11q deletion, or any combination thereof, comprising identifying a human in need of treatment for chronic lymphocytic leukemia and having one of said deletion or mutations, and administering to said human a therapeutically effective amount of a compound of formula I: or a pharmaceutically acceptable salt thereof,; wherein the compound or the pharmaceutically acceptable salt thereof is the only anti-cancer therapy administered to the human; and wherein the human is (i) refractory to at least one anti-cancer treatment, or (ii) in relapse after treatment with at least one anti-cancer therapy, or a combination thereof; wherein about 500 mg to about 1000 mg of the compound of formula I, or a pharmaceutically acceptable salt thereof, is administered to the human twice daily.